VERVE-102 is given as one-time IV injection to people with severe inherited high cholesterol who still have high LDL levels despite taking all available cholesterol-lowering pills.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether single-dose gene-editing therapies for PCSK9 in HeFH patients achieve durable LDL-C reduction with acceptable safety compared to repeated dosing or conventional therapies.
A systematic review and meta-analysis of all published trials of single-dose gene-editing therapies targeting PCSK9 in HeFH or familial hypercholesterolemia, comparing safety profiles, LDL-C reduction durability, and need for retreatment over 3 years.
Whether a single infusion of VERVE-102 is safer or more effective than daily statin therapy in patients with HeFH and uncontrolled LDL-C.
A double-blind RCT of 200 adults with HeFH and LDL-C ≥100 mg/dL on maximally tolerated statins and ezetimibe, randomized to single VERVE-102 infusion vs. continued standard care, with primary endpoints of safety events and LDL-C change at 52 weeks.
Whether patients with HeFH receiving single-dose VERVE-102 maintain LDL-C reduction and avoid cardiovascular events over 5 years compared to historical controls on oral therapy.
A prospective cohort study of 300 HeFH patients receiving single-dose VERVE-102, matched 1:2 with historical controls on maximal oral therapy, tracking LDL-C levels annually and major cardiovascular events over 5 years.
What proportion of patients with HeFH and uncontrolled LDL-C are eligible for single-dose gene-editing therapy based on current inclusion criteria.
A cross-sectional survey of 1,000 patients with HeFH across 10 lipid clinics, assessing eligibility for single-dose gene-editing therapy based on LDL-C levels, prior therapies, and comorbidities.
Whether individual patients with complex comorbidities or prior adverse reactions to lipid-lowering drugs can safely receive VERVE-102.
Detailed reporting of 5–10 patients with HeFH and complex medical histories (e.g., prior statin intolerance, liver disease, autoimmune conditions) who received VERVE-102, documenting safety and tolerability.